Many clinical trials are in progress that involve the collection of patient-level data
INTRODUCTION
CLINICAL TRIALS OF alternative health care interventions are increasingly collecting patient-level data on both the health outcome and resource consequences of the interventions under evaluation. Where a new intervention is both more costly and more effective than an alternative, it is appropriate to consider whether the additional cost is justified by the additional health benefits produced. In such situations, it is the incremental cost effectiveness ratio that summarizes the value for money of the new intervention. Much attention in the recent literature has been devoted to problems of estimating confidence limits for incremental cost-effectiveness ratios at the data analysis stage of an evaluation. A number of commentators have highlighted that, at the design stage, sample size calculations should be based not only on the clinical endpoints of the trial but also on the economic endpoints (1-4). A recent paper demonstrated how a sample size formula for cost-effectiveness analysis can be derived from the independent confidence intervals on cost and effect differences (5) . One of the acknowledged weaknesses of the approach is that it fails to allow for the covariance between the cost and effect differences.
In this paper, we demonstrate how a sample size formula, based on the net-benefit approach to interpreting cost-effectiveness results (6, 7) , allows for covariance and is, therefore, more efficient than that originally proposed by Briggs and Gray. It is shown that the sample size formula proposed by Briggs and Gray is a special case of the general formula presented in this paper. We then go on to demonstrate how, at the analysis stage, the net benefit approach to decision making is formally equivalent to decision making based on the cost-effectiveness plane. We suggest that the appropriate way to represent uncertainty in the decision making process is through cost-effectiveness acceptability curves (8), rather than by confidence intervals around either net-benefit values or cost-effectiveness ratios.
COST-EFFECTIVENESS AND DECISION RULES
Suppose that two treatments are to be compared in a clinical trial setting. One treatment represents the currently provided (or control) therapy and the other represents an experimental (or treatment) therapy. The true (but unobservable) health outcome effects of the two therapies are denoted by pLT and pac for the treatment and control therapies, respectively. Similarly, the true (but unobservable) resource costs associated with the two treatments are denoted pcr and pee. O'Brien and colleagues identify four situations that can arise in relation to the incremental cost and effectiveness of two therapies (2):
1. pCr -pcc < 0; pm -pEC > 0; dominance-accept new treatment as it is both cheaper and 2. pn -pCc > 0; pm -pEC < 0; dominance-reject new treatment as it is both more expensive 3. pCr -pCc > 0; pL7 -pLEC > 0; trade-of-consider the magnitude of the additional cost of 4. pcr -pCc < 0; par -pEc < 0; trade-of-consider the magnitude of the cost-saving of the more effective than the existing therapy, and less effective than the existing therapy, the new therapy relative to its additional effectiveness, and new therapy relative to its reduced effectiveness.
These four situations correspond to the four quadrants of the cost-effectiveness (CE) plane, which has been proposed for presenting cost-effectiveness results (9,lO) . The CE plane is presented in Figure 1 . Where one intervention is simultaneously cheaper and more effective than the other (Situations 1 and 2 above and the southeast (SE) and northwest (NW) quadrants on the CE plane) it is clearly the treatment of choice since it dominates the alternative intervention. However, where one intervention is both more effective and more costly (Situations 3 and 4 above and the northeast (NE) and southwest (SW) quadrants on the cost-effectiveness plane) then the decision is no longer clear. Rather, a judgment must be made concerning whether the difference in effectiveness resulting from a switch in therapy is justified given the difference in costs that such a switch would bring about. In order to aid such judgment, an incremental cost-effectiveness ratio (ICER) should be calculated that provides a summary of the cost-effectiveness of one intervention relative to the other:
In the absence of the simple case of dominance, the decision over which is the appropriate treatment to implement cannot be determined unless a cut-off value, or maximum willingness to pay for additional health effect (RC), has been specified (11) . This ceiling value of the ICER can be represented by the (slope of the) dashed line on the CE plane of Figure 1 . If the incremental costs and effects are plotted to the right of this line on the CE plane, then the treatment is considered cost-effective, while points to the left of this line represent costineffective interventions. (In principle, a new treatment might be introduced if it was less effective than the existing treatment, but was sufficiently less costly to compensate for that loss of effect [ie, to the right of the line representing the ceiling ratio in the SW quadrant of the CE plane]. In reality, such a policy might raise ethical objections from those who believe it unjust to withdraw a treatment that has formerly been available. Since, at a design stage, it is unlikely that a trial will be undertaken to show an experimental therapy to be less effective than an existing therapy, we assume that only new treatments that are thought to be more effective than existing treatments will progress to evaluation).
In terms of the ICER, the decision rule is that the new treatment should be implemented instead of the standard treatment if
In a trial situation, on the basis of data collected from two groups of patients receiving the alternative therapies, the ICER can be estimated by:
where cT and ec are the mean costs in the treatment and control arms of the trial, respectively, and E, and Ec are the mean effects.
Due to the uncertainty associated with sampling variation, many would argue that the decision rule to implement the new treatment should be based on the requirement that the observed ICER from Equation 2 be significantly less than the ceiling cost-effectiveness ratio, R,, which is appropriate for decision making purposes. In other words, it is appropriate to test the null hypothesis Ho: pAc/pAE > R, against the alternative hypothesis H, : pAc/ Although the underlying cost and effect data may not follow a well-behaved distribution in general, the central limit theorem states that the sample mean costs and effects in Equation 2 will approach a normal distribution with increasing sample size. Hence, with sufficient sample size, the distribution of the relevant estimators can be approximated by normal distributions with the following mean and variance:
where o2 represents the true population variance for (subscripts) costs (C) and effects (E) for the treatment (T) and control (C) groups.
As it is known that the sum of two normal variables is itself normally distributed, we can assume that the estimates of the incremental costs and effects, the numerator and denominator of the estimated ICER from Equation 2, are distributed:
where:
(Note that implicit in this assumption of the variance of the cost and effect differences in Equation 3 is that the data were generated from independent groups. However, for some study designs, such as, for example, a before and after study or a cross-over mal, the independence assumption may not be justified and the above expressions should incorporate a covariance term.)
As a ratio of two asymptotically normal variables, the ICER suffers from the problem that its moments may not be defined, due to the nonnegligible probability that the denominator of the ratio could take a zero value. Given the intractable nature of the variance of the ratio, many papers have focused on the possibility of estimating confidence limits for the ICER which do not involve a measure of variance (2, 12, 13, 14) .
More recently, two papers highlighted the 'net-benefit' approach to handling uncertainty in cost-effectiveness analysis (6,7). The decision rule of Equation 1 can be rearranged to give a measure of 'net-benefit' and an associated decision rule that the new therapy should be implemented only if the net-benefits are positive. Two alternative formulations of netbenefit have been suggested based on a simple rearrangement of Equation 1, such that the new therapy should be implemented over the existing treatment if
or, equivalently, if
In Equation 4, the net-benefits are measured in monetary terms (6), while in Equation 5, the net-benefits are measured in terms of health (7).
The advantage of the net-benefits approach is that the (1 -a)% confidence interval for net-benefits can be easily determined in the standard fashion, as:
where NB is the estimated net-benefit measure, with variance oiB, and zaI2 is the critical value from the standard normal distribution. In contrast to a ratio, whose variance may not be defined, the variance of net-benefits is simply a linear combination of two asymptotically normal variables and can, therefore, be defined as:
in terms of the net monetary benefit measure of Equation 4, or:
for the net health benefit measure of Equation 5.
SAMPLE SIZE FOR COST-EFFECTIVENESS ANALYSIS
We now show how the net-benefits approach can be used to generate a sample size formula for cost-effectiveness analysis. In this section, the monetary version of net-benefits from Equations 4 and 6 is employed. However, an exactly equivalent formula, which generates the same sample size, can be derived using the net health benefit approach from Equations 5 and 7. An observed net monetary benefit is significantly positive providing:
Although it is tempting to base the sample size calculation on the numbers of patients required to show an observed difference as significant, sample size calculations should be based on the hypothesized cost and effect differences (denoted AI?,AO such that the study has the appropriate power to detect the net benefit as different from zero. In algebraic terms:
where zb is the critical value from the standard normal distribution corresponding to a required power of 1 -p.
Noting that the cov(x, y) = p d -(where p is the correlation coefficient), the variance of net benefits from Equation 6 can be expressed in terms of the variance of the cost and effect differences from Equation 3 and the correlation coefficient between those differences:
Substituting the above expression for the variance of net benefits into Equation 8 and assuming equal sample sizes for each arm of the ma1 gives the sample size formula (after rearranging on n) as:
It is straightforward to show (see appendix) that the sample size formula generated by Briggs and Gray (5) is simply a special case of the general formula in Equation 9 above when the correlation between cost and effect differences is set to -1. This is because the sample size formula in their paper was based on the 'confidence box' approach to confidence interval estimation for an ICER (2) which implicitly assumes that cost and effect differences are perfectly negatively correlated such that the combination of the 95% confidence limits on cost and effect differences generates a 95% confidence limit for the ICER. Where cost and effect differences are not perfectly correlated, the confidence box method will produce a confidence interval for the ratio that is greater than the nominal 95% level. Moreover, the required sample size will be overstated when using the confidence box method if p > -1, since it can be shown that the sample size formula is a decreasing function of the correlation (see appendix).
A NUMERICAL EXAMPLE: THE DESIGN STAGE
In order to illustrate the sample size calculations outlined above, we present a numerical example based on the same formula as that employed by Briggs and Gray (5) . Their example assumed that a randomized trial was planned, based on an effect difference in favor of a new therapy of 0.8 life-years at an additional cost over standard therapy of $1,200 (ie, a hypothesized ICER of $1,200/0.8 = $1,500 per life year gained). The assumed standard deviations for the effects and costs (assuming they were the same in each arm) were 4.04 and 8700, respectively. First, we assume that cost and effect differences are independent, such that the correlation coefficient is zero and the correlation term from Equation 9 can be ignored. In order to employ the power calculation formula of Equation 9 , we have only to estimate the appropriate cost-effectiveness ceiling ratio from which we want to have the power to be able to detect the observed cost-effectiveness ratio as significantly different from. Since no such universally accepted ceiling ratio exists for decision making purposes we suggest that analysts plot the sample size requirements as a function of the maximum cost-effectiveness ratio, for different levels of study power (and perhaps even significance). Figure 2 shows such a presentation for the example detailed above and is directly compara- ble to Figure 7 of the Briggs and Gray paper. Sample size requirements are shown for values of the maximum cost-effectiveness ratio between approximately $3,000 per life year and $30,000 per life year and for study power of 50% to 90%, assuming conventional 5% significance. Also shown is the sample size based only on the effectiveness outcome (the horizontal line at n = 536) and the equivalent 90% power sample size calculation (dotted line) based on the Briggs and Gray sample size formula (ie, assuming that the correlation is equal to -1). From Figure 2 it appears that the sample size required for a trial is a decreasing function of R,. Intuitively, this seems reasonable since a higher ceiling ratio indicates a greater willingness to pay for health benefits which, in turn, implies a greater net-benefit suggesting that fewer observations are required to establish the net-benefits as significant. However, this is not always true. Consider Figure 3 , which shows the sample size requirements based on different assumptions concerning the correlation between cost and effect differences for the example, based on 90% power and 5% significance. The figure shows that a very strong positive correlation between cost and effect differences may actually cause the sample size to be an increasing function of R, in the example. In general, whether sample size is increasing or decreasing in R, will depend on both the sign and the magnitude of the covariance. It can be shown that there will be a critical value of the correlation between cost and effect that will mean that the sample size requirement for the clinical study and the sample size requirement for an economic study based on the same effectiveness measure will be equal (see appendix). (Since the correlation coefficient must lie between -1 and +1 by definition, critical values of the coefficient outside of this range indicate that there is no covariance between cost and effect differences that would lead to the sample size requirements for the clinical and economic evaluations in question being equal.)
For example, it is clear from Figure 3 that the sample size for economic evaluation will exceed that for clinical evaluation unless the correlation coefficient is very high. In general, it is likely that sample sizes for economic analysis will exceed those for clinical analysis where a new treatment is hypothesized to be both more effective and also more expensive. The extremely high correlation coefficients required to make sample size increase in R, are unlikely to be observed in practical application.
COST-EFFECTIVENESS RATIOS OR NET BENEFITS?
Using the net-benefit approach at the design stage would seem to imply that at an analysis stage the outcome of interest in the economic analysis is the net-benefit measure rather than the cost-effectiveness ratio. While some authors have suggested the net-benefit approach as a way to avoid the problems associated with confidence intervals around ratios (6) others have gone further, suggesting that net (health) benefits themselves may be a more appropriate framework in which to examine the results of cost-effectiveness analyses (7) . Since the decision rules of net-benefit are the same as cost-effectiveness the choice of how to present results comes down to personal preference. While net benefits have convenient statistical properties we prefer to present results in terms of cost-effectiveness ratios. We show how a net-benefit approach is equivalent to appropriate decision making on the cost-effectiveness plane, by means of an example and we introduce the cost-effectiveness acceptability curve as a method of presenting results that directly addresses the original study question of whether an intervention is cost-effective.
A NUMERICAL EXAMPLE: THE ANALYSIS STAGE
Consider Table 1 , which presents the results from a (hypothetical) clinical trial in terms of the cost and effects of two alternative interventions. As the new treatment is both more effective and more costly it is necessary to calculate an incremental cost-effectiveness ratio. This shows the cost-effectiveness of the new treatment relative to the control treatment as $4,836 per unit of health effect. Whether the new treatment should be implemented depends on the maximum willingness to pay for additional health effect, R,. Suppose this is known to be $lO,O00. It would appear that the new treatment should be implemented since its cost- effectiveness is below the ceiling ratio. Table 1 However, this analysis is based purely on point estimates of observed cost and effect. In order to allow for sampling variation, confidence limits for the ICER and net-benefit statistics could be calculated and the new treatment only implemented if the treatment is found to be significantly cost-effective. An undoubted advantage of the net-benefit statistics is that they have a mathematically tractable variance and an asymptotically normal sampling distribution, which means that for sufficient sample sizes (Cost data are commonly skewed-sample sizes required for the normality assumption to be tenable will increase with the level of skewness in the data.), the confidence intervals are straightforward to calculate using standard methods. By contrast, the variance of a ratio statistic is intractable and its sampling distribution is undefined.
Although parametric methods, such as Fieller's theorem, have been suggested for estimating confidence limits for ratio statistics, in this example we employ the nonparametnc method of bootstrapping since this allows us to 'visualize' uncertainty due to sampling variation on the CE plane. The bootstrap approach has been advocated by a number of commentators for estimating confidence limits for ICERs (2, 13, 15, 16) and has also been suggested by advocates of the net-benefit approach (7). Furthermore, the bootstrap method has been used to handle the skewness that commonly arises with cost data (5).
The bootstrap approach can be characterized as a simple four-step process:
1. Sample with replacement n, codeffect pairs from the sample of patients who received the new treatment and calculate the bootstrap estimates c: and l?: for the bootstrap sample, 2. Sample with replacement nc cost/effect pairs from the sample of patients receiving the control treatment and calculate the bootstrap estimates c*, and I?*, for the bootstrap sample, 3. On the basis of these four means, estimate the cost and effect differences, A P and u*, and 4. On the basis of these cost and effect differences calculate either the bootstrap ICER or the bootstrap net-benefit.
This process is then repeated many times to build up the empirical estimate of the sampling distribution of the relevant statistic. Straightforward confidence limits can then be estimated using the 2.5th and 97.5th percentiles of the ordered list of bootstrap replications (Alternatively, more efficient methods of calculating confidence intervals, such as the bias-corrected and bias-corrected-accelerated methods [ 171 can be applied to the problem of the ICER [ 161. However, these are not discussed here in order to keep the example simple and because the need for these corrections largely arises from the problems associated with confidence intervals for ratio estimators. However, should the bootstrap indicate residual skewness in the sampling distribution of net benefits, it may be appropriate to apply the bias corrected method to account for this.). The confidence limits based on the bootstrap percentile approach are reproduced in Table  1 adjacent to the appropriate statistic. For comparison, the parametric net-benefit intervals are also presented. Since both of the net-benefit intervals include zero and the upper limit of the ICER confidence interval is greater than $lO,OOO, it cannot be concluded that the new treatment is cost-effective at the conventional 5% significant level. However, suppose a decision has to be made concerning which of the two treatments should be provided for the patients in question. Given that the baseline results from Table 1 indicate that the new treatment is cost-effective, the decision maker may be interested in the overall confidence that can be attached to a decision to implement the new therapy, even if that confidence does not reach conventional levels. This situation often arises in economic evaluations that have not been powered on the economic outcomes-rather analysts are forced to work within the sample size constraints of the original study.
The cost and effect differences, from 1OOO repetitions of the first three steps of the bootstrap process based on the raw data summarized in Table I , are presented in Figure 4 . Note that in this example, the bootstrap replications fall into three of the four quadrants of the cost-effectiveness plane. In the SE and NW quadrants of the cost-effectiveness plane, the bootstrap replications of cost and effect will generate negative ratios. However, the negative ratios in the SE quadrant are associated with the new treatment dominating the old, whereas the negative ratios in the NW quadrant are associated with the old treatment dominating the new treatment. However, in a rank ordering of cost-effectiveness ratios all negative ratios are grouped together and are not distinguished by which quadrant of the cost-effectiveness plane they fall into. The problem is that the ICER does not summarize all relevant information when uncertainty extends into more than one quadrant of the CE plane. This problem generates problems of interpretation and gives us good reason to be wary of bootstrap-based confidence limits when some replications fall into the NW quadrant of the plane (ie, when effect differences are negative) (1 8) .
Note that this problem does not arise with the net-benefit approach. Positive net benefits are favorable to the new treatment and negative net benefits are prejudicial to the new treatment. Hence, simply calculating the proportion of positive net-benefit observations in the bootstrap replications gives an estimate of the likelihood that can be given to the new treatment being cost-effective. In the example illustrated above, this probability is 82.4%. Hence, even though the confidence limits for net-benefits include zero at the 5% significance level, a decision maker may decide that an 82.4% probability that the new treatment is costeffective gives sufficient confidence in the new treatment to recommend implementation.
However, if we recognize the need to base decision making on the cost-effectiveness plane, rather than purely on confidence intervals for cost-effectiveness ratios, we get the same results as the net-benefit approach. So far, we have assumed that the maximum willingness to pay for additional health effect is known. However, considerable uncertainty remains concerning the ceiling ratio. One approach is to plot the net benefit, together with confidence limits, as a function of the ceiling ratio (7) . An alternative, and we believe more informative approach, is to present the cost-effectiveness acceptability curve, first advocated by van Hout and colleagues (8) . This shows the likelihood that the treatment under consideration is cost-effective as a function of the ceiling ratio. Figure 5 shows the cost-effectiveness acceptability curve for the above example based on the bootstrap replications of the cost and effect differences. Note that the cost-effectiveness acceptability curve is exactly the same, no matter whether it is calculated using the netbenefit or the cost-effectiveness plane approach. This is because the decision rules for both approaches are the same. Hence, if we move away from the debate about confidence intervals (either for net benefits or ICERs) and accept that cost-effectiveness acceptability curves generate the appropriate information for decision makers, it does not matter which approach we adopt.
It is common for the vertical axis of acceptability curves to be labeled 'probability costeffective' (as in Figure 5 ). It should be noted however, that such an interpretation requires a Bayesian view of probability. A number of commentators have shown that such acceptability curves as those shown in Figure 5 are equivalent to a Bayesian analysis using an uninformative prior distribution for cost-effectiveness (19,20,2 1).
CONCLUSIONS
The net-benefit approach to cost-effectiveness analysis is a powerful approach. The properties of the net-benefit statistic mean that it has many practical advantages over the ICER statistic when it comes to representing uncertainty in the form of confidence intervals. We show how, at the design stage of a trial intending to collect both health outcome effect and resource cost data, the net-benefits approach can be employed to generate a more efficient samplesize formula for cost-effectiveness analysis, and that the previously suggested formula based on cost-effectiveness ratios is simply a special case of our more general formula. At the analysis stage of an economic analysis, it is natural to report point estimates of costeffectiveness using the ICER rather than net benefits as we believe this statistic remains the most straightforward to interpret. Rather than presenting confidence intervals for either costeffectiveness ratios or net benefits, we believe that cost-effectiveness acceptability curves offer more information to the decision maker, since they make no assumptions concerning the appropriate level of significance or the maximum willingness for an additional unit of health effect appropriate for decision making purposes. Furthermore, they directly address the study question of whether the intervention under evaluation is cost-effective. Using the nonparametric approach of bootstrapping, we show that cost-effectiveness acceptability curves can equivalently be calculated using either a net-benefit approach or a cost-effectiveness approach to decision making. However, due to the desirable properties of the net-benefit statistic, the calculation of cost-effectiveness acceptability curves is much more straightforward using a net-benefits approach.
APPENDIX Proposition 1: The Briggs and Gray Sample Size Formula is a Special Case of Our More General Formula
Setting the correlation coefficient in Equation 9 to -1 gives:
The term in the square brackets is simply the square of R , d a + d m simplifying the expression to:
which is exactly the same as Equation 9 in the paper by Briggs and Gray (5).
Proposition 2: The Required Sample Size i s Decreasing in the Correlation
Treating the sample size formula of Equation 9 as an identity and differentiating with respect to the correlation coefficient gives:
Since R,, the power and significance levels, the variances, and the denominator term must all be positive, the partial derivative above is always negative and the sample size is, therefore, a decreasing function of the correlation coefficient.
Proposition 3: The Required Sample Size May be Increasing in R,
Treating the sample size formula of Equation 9 as an identity and differentiating with respect to R, gives:
Setting this partial derivative to zero and rearranging on the correlation coefficient gives:
Hence, this expression gives the value for the correlation coefficient at which the sample sizes generated by a formula based just on effectiveness and a formula based on cost-effectiveness are equal (for the same effectiveness measure). Where the correlation coefficient is greater than that given by the identity above, the sample size will be an increasing function of the ceiling ratio. Of course, since -1 < p < 1 it will not always be the case that there exists a correlation coefficient such that the sample sizes required for cost-effectiveness analysis and clinical evaluation are equal.
